facilities on the CERCLA National Priorities List (NPL). Among these statutory provisions is that the Administrator of ATSDR prepare toxicological profiles for substances included on the priority lists of hazardous substances. These lists identified 275 hazardous substances that ATSDR and EPA determined pose the most significant potential threat to human health. The availability of the revised priority list of 275 hazardous substances was announced in the Federal Register on February 28, 1994 (59 FR 9486). For prior versions of the list of substances see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); and October 28, 1992 (57 FR 48801). CERCLA also requires ATSDR to assure the initiation of a research program to fill data needs associated with the substances.

Section 104(i)(3) of CERCLA [42 U.S.C. 9604(i)(3)] outlines the content of these profiles. Each profile is required to include an examination, summary and interpretation of available toxicological information and epidemiologic evaluations. This information and these data are to be used to ascertain the levels of significant human exposure for the substance and the associated health effects. The profiles must also include a determination of whether adequate information on the health effects of each substance is available or in the process of development. When adequate information is not available, ATSDR, in cooperation with the National Toxicology Program (NTP), is required to assure the initiation of research to determine these health effects.

Although key studies for each of the substances were considered during the profile development process, this Federal Register notice is to solicit any additional studies, particularly unpublished data and ongoing studies, for possible addition to the profiles now or in the future.

The following draft toxicological profiles are expected to be available to the public on or about October 17, 1995.

Document	Hazardous substance	CAS No.
1	Benzene	000071–43–2
2	Chlorfenvinfos	470–90–6
3	Chloroform	000067–66–3
4	Chlorpyrifos	002921–88–2
5	Cyanide	000057–12–5
	Ammonium Thiocyanate.	001762–95–4
	Cyanazine	021725–46–2
	Hydrogen Cyanide ...	000074–90–8
	Sodium Cyanide	000143–33–9
	Thiocyanate	000302–04–5
	Potassium Cyanide .	151–50–8
	Calcium Cyanide	592–01–8
	Copper(I) Cyanide ...	544–92–3
	Potassium Silver Cyanide.	506–61–6
	Cyanogen	460–19–5
	Cyanogen Chloride ..	506–77–4
6	Dichlorvos	62–73–7
7	Nickel	007440–02–0
	Nickel Chloride	007718–54–9
	Nickel Oxide	1313–99–1
	Nickel Sulfate	7786–81–4
	Nickel Subsulfide	12035–72–2
	Nickel Acetate	373–02–4
	Nickel Nitrate	13138–45–9
8	Polychlorinated Biphenyls.	001336–36–3
	Aroclor 1016	012674–11–2
	Aroclor 1221	011104–28–2
	Aroclor 1232	011141–16–5
	Aroclor 1242	053469–21–9
	Aroclor 1248	012672–29–6
	Aroclor 1254	011097–69–1
	Aroclor 1260	011096–82–5
	Aroclor 1262	37324–23–5
	Aroclor 1268	11100–14–4
9	Tetrachloroethylene .	000127–18–4
10	Trichloroethylene	000079–01–6
11	Vinyl Chloride	000075–01–4

All profiles issued as ''Drafts for Public Comment'' represent the agency's best efforts to provide important toxicological information on priority hazardous substances in compliance with the substantive and procedural requirements of Section 104(i)(3) of CERCLA, as amended. As in the past, we are seeking public comments and additional information which may be used to supplement these profiles. ATSDR remains committed to providing a public comment period for these documents as a means to best serve public health and our clients.

Dated: October 24, 1995.

Claire V. Broome,

Deputy Administrator, Agency for Toxic Substances and Disease Registry.

[FR Doc. 95–26824 Filed 10–27–95; 8:45 am]

BILLING CODE 4163–70–P

[ATSDR–101]

Availability of Final Toxicological Profiles

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS).

ACTION: Notice of availability.

SUMMARY: This notice announces the availability of five final and six updated final toxicological profiles of priority hazardous substances comprising the seventh set prepared by ATSDR.

FOR FURTHER INFORMATION CONTACT: Ms. Kim E. Jenkins, Agency for Toxic Substances and Disease Registry, Division of Toxicology, 1600 Clifton Road, NE., Mailstop E–29, Atlanta, Georgia 30333, telephone (404) 639–6357.

SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization Act (SARA) (Pub. L. 99–499) amends the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or Superfund) (42 U.S.C. 9601 et seq.) by establishing certain requirements for ATSDR and the Environmental Protection Agency (EPA) with regard to hazardous substances which are most commonly found at facilities on the CERCLA National Priorities List (NPL). Among these statutory requirements is a mandate for the Administrator of ATSDR to prepare toxicological profiles for each substance included on the priority lists of hazardous substances. These lists identified 275 hazardous substances that ATSDR and EPA determined pose the most significant potential threat to human health. The availability of the revised list of the 275 most hazardous substances was announced in the Federal Register on February 28, 1994 (59 FR 9486). For prior versions of the list of substances see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166) and October 28, 1992 (57 FR 48801).

Notice of the availability of drafts of the seventh set of 11 toxicological profiles for public review and comment was published in the Federal Register on October 18, 1993 (57 FR 53739), with notice of a 90-day public comment period for each profile, starting from the actual release date. Following the close of each comment period, chemical-specific comments were addressed, and where appropriate, changes were incorporated into each profile. The public comments, the classification of and response to those comments, and other data submitted in response to the Federal Register notice bear the docket control number ATSDR–75. This material is available for public inspection at the Division of Toxicology, Agency for Toxic Substances and Disease Registry, Building 4, Suite 2400, Executive Park Drive, Atlanta, Georgia, (not a mailing address) between 8 a.m. and 4:30 p.m., Monday through Friday, except legal holidays.

Availability

This notice announces the availability of five final and six updated final toxicological profiles comprising the seventh set. The following toxicological profiles are now available through the U.S. Department of Commerce, National Technical Information Service (NTIS), 5285 Port Royal Road, Springfield, Virginia 22161, telephone 1–800–553–6847. There is a charge for these profiles as determined by NTIS.

Toxicological profile	NTIS Order No.	CAS No.
Seventh Set:		
1. Asbestos (UPDATE)	PB95–264305	1332–21–4
Actinolite		13768–00–8
Amosite		12172–73–5
Anthophyllite		17968–78–9
Chrysotile		12001–29–5
Crocidolite		12001–28–4
Tremolite		14567–73–8
2. Benzidine (UPDATE)	PB95–264313	92–87–5
3. Dinitrocresols	PB95–264321	2167–18–9
4,6-Dinitro-O-cresol		534–52–1
Dinitro-O-cresol		335–85–9
		497–56–3
Dinitro-P-cresol		609–93–8
		63989–82–2
Dinitro-M-cresol		616–73–9
4. Dinitrophenols	PB95–264339	.....
2,4-Dinitrophenol		51–28–5
2,6-Dinitrophenol		573–56–8
2,5-Dinitrophenol		329–71–5
2,3-Dinitrophenol		66–56–8
3,5-Dinitrophenol		586–11–8
3,4-Dinitrophenol		577–71–5
5. Disulfoton	PB95–264347	298–04–4
6. Mirex	PB95–264354	2385–85–5
Chlordecone		143–50–0
7. Naphthalene (UPDATE)	PB95–264362	91–20–3
2-Methylnaphthalene		91–57–6
1-Methylnaphthalene		90–12–0
8. Polycyclic Aromatic Hydrocarbons (PAHs) (UPDATE)	PAHs	PB95–264370
Acenaphthene		83–32–9
Acenaphthylene		208–96–8
Anthracene		120–12–7
Benzo(a)anthracene		56–55–3
Benzo(a)pyrene		50–32–8
Benzo(e)pyrene		192–97–2
Benzo(b)fluoranthene		205–99–2
Benzo(j)fluoranthene		205–82–3
Benzo(k)fluoranthene		207–08–9
Benzo(g,h,i)perylene		191–24–2
Chrysene		218–01–9
Dibenzo(a,h)anthracene		53–70–3
Fluoranthene		206–44–0
Fluorene		86–73–7
Indeno(1,2,3-cd)pyrene		193–39–5
Phenanthrene		85–01–8
Pyrene		129–00–0
9. Polybrominated Biphenyls (PBBs)	PB95–264388	.....
Hexabromobiphenyls		67774–32–7
		59536–65–1
		36355–01–8
Octabromobiphenyls		612288–13–9
Decabromobiphenyls		13654–09–6
		39282–95–6
10. 1,1,1-Trichloroethane (UPDATE)	PB95–264396	71–55–6
11. Xylenes (UPDATE)	PB95–264404	1330–20–7

Dated: October 24, 1995.

Claire V. Broome,

Deputy Administrator, Agency for Toxic Substances and Disease Registry

[FR Doc. 95–26826 Filed 10–27–95; 8:45 am]

BILLING CODE 4163–70–P

Centers for Disease Control and Prevention (CDC)

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) Announces the Following Meeting

Name: Review of the proposed protocol for the study: ''Epidemiologic Study of Adult Leukemia and Workplace Exposure to Ionizing Radiation.''

Time and Date: 9 a.m. to 4:30 p.m., November 28, 1995.

Place: Alice Hamilton Laboratory, Conference Room C, NIOSH 5555 Ridge Avenue, Cincinnati, Ohio 45213.

Status: Open to the public for observation and comment, limited only by space available.

Purpose: The purpose of this meeting is to obtain individual advice and guidance regarding the technical and scientific merits of the proposed epidemiologic study of adult leukemia and workplace exposure to ionizing radiation being conducted by NIOSH investigators. Participants will review the proposed study protocol, recommend changes based on scientific merit, and advise on the conduct of the study. Viewpoints and suggestions from industry, labor, academia, other government agencies, and the public are invited.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Thurman Wenzl, Sc.D., Research Industrial Hygienist, Health-Related Energy Research Branch, Division of Surveillance, Hazard Evaluations and Field Studies, NIOSH, 4676 Columbia Parkway, M/S R–44, Cincinnati, Ohio 45226, telephone 513/841–4490.

Dated: October 23, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–26809 Filed 10-27–95; 8:45 am]

BILLING CODE 4163–19–M

Lung Cancer and Diesel Exhaust Among Non-Metal Miners; Cohort Mortality Study With Nested Case-Control Study; Meeting

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Review of proposed protocol for the study: ''A Cohort Mortality Study with a Nested Case-control Study of Lung Cancer and Diesel Exhaust among Non-metal Miners.''

Time and Date: 9 a.m.–5 p.m., November 27, 1995.

Place: Room 503–A, Hubert H. Humphrey Building, 200 Independence Avenue, SW, Washington DC 20201.

Status: Open to the public for observation and comment, limited only by the space available. The room accommodates approximately 50 people.

Purpose: The purpose of the meeting is to obtain comment and guidance regarding the technical and scientific merits of the study: ''A Cohort Mortality Study with a Nested Case-control Study of Lung Cancer and Diesel Exhaust among Non-metal Miners,'' being conducted jointly by NIOSH and NCI.

Matters to be Discussed: Agenda items include short presentations concerning the study protocol by the study investigators, comments from the review panel members, responses and discussion of the submitted comments, and discussion open to all meeting attendees. Viewpoints and suggestions from industry, labor, academia, other government agencies, and the public are invited. Written comments will be part of the review, and should be received by the contact person listed below no later than November 13, 1995.

Contact Person for More Information: Michael D. Attfield, Ph.D., NIOSH Project Director, NIOSH, Division of Respiratory Disease Studies, (DRDS), Mailstop 234, 1095 Willowdale Road, Morgantown, West Virginia 26505–2888, telephone 304/285–5751.

Dated: October 19, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–26810 Filed 10–27–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 95N–0343]

In Vitro Diagnostic Devices; Tier/Triage Management Initiative; Notice of Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public workshop to consider a tier/triage management initiative for in vitro diagnostic devices (IVD's). This management initiative is intended to improve the balance between FDA resources and workload based on a tier/triage device risk assessment. The purpose of the workshop is to obtain public comments and suggestions that will help FDA assess potential extensions and applications of the tier/triage management initiative of the Office of Device Evaluation (ODE), Center for Devices and Radiological Health (CDRH). A transcript of the meeting will be available from the Dockets Management Branch (address below).

DATES: The public workshop will be held on October 30, 1995, from 9 a.m. to 4 p.m. Submit written notices of participation as soon as possible.

ADDRESSES: The public workshop will be held at the Parklawn Building, conference rooms D and E, 5600 Fishers Lane, Rockville, MD. Submit written requests to make a presentation at the meeting, including an outline of comments, to Kaiser Aziz or Clara Sliva, FAX 301–594–5941. Submit written comments on the management initiative to the Dockets Management Branch, (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857. A transcript of the meeting will be available through the Dockets Management Branch. A limited number of overnight accommodations have been reserved at the Doubletree Hotel, Rockville, MD. Attendees requiring overnight accommodations may contact the hotel at 301–468–1100 and reference the FDA meeting group: ''GBG.'' Reservations will be confirmed at the group rate based on availability. Persons with disabilities who require special assistance to attend or participate in the workshop can be accommodated if advance notification is provided to Sociometrics, Inc., Alice Hayes, 8300 Colesville Rd., suite 550, Silver Spring, MD 20910, or FAX 301–608–3542. The availability of appropriate accommodations cannot be assured unless prior notification is provided. There is no registration fee for this meeting.

FOR FURTHER INFORMATION CONTACT: Kaiser Aziz, or Clara Sliva, Center for Devices and Radiological Health (HFZ–440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–3084, FAX 301–594–5941.

SUPPLEMENTARY INFORMATION:

Over the past few years, ODE, CDRH, has made an effort to raise the quality of the premarket review of medical devices. In the Division of Clinical Laboratory Devices (DCLD) this has resulted in a movement from a descriptive to a data driven review process with emphasis on using voluntary standards or published design or statistical methodologies as a basis for product review. One consequence of this heightened review process has been an imbalance between workload and workforce resulting in a backlog of submissions.